Cholinergic system dysfunction and neurodegenerative diseases: Cause or effect?

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 7, 2014, Pages 1294-1303

  Tata, Ada M ^a,b   Velluto, Lucia ^c   D’angelo, Chiara ^d   Reale, Marcella ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Center for Research in Neurobiology 'Daniel Bovet'   (Italy)

^c Villa Serena Hospital   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Acetylcholine; Cholinergic receptors; Inflammation; Neurodegenerative diseases

Indexed keywords

ACETYLCHOLINE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CHOLINE ACETYLTRANSFERASE; GALANTAMINE; HUNTINGTIN; VESICULAR ACETYLCHOLINE TRANSPORTER;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; AUTONOMIC NEUROPATHY; BRAIN REGION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHOLINERGIC SYSTEM; COGNITION; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; EMBRYO DEVELOPMENT; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROTRANSMISSION; PARKINSON DISEASE; SCHIZOPHRENIA; ANIMAL; CENTRAL NERVOUS SYSTEM; IMMUNOMODULATION; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACETYLCHOLINE; ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; NEURODEGENERATIVE DISEASES; NEUROIMMUNOMODULATION;

EID: 84911378828     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140917121132     Document Type: Article

References (119)

1. Tata AM, De Stefano ME, Srubek Tomassy G, et al. Subpopulations of rat dorsal root ganglion neurons express active vesicular acetylcholine transporter. J Neurosci Res 2004; 75: 194-202.
2. Bernardini N, Srubek Tomassy G, Tata AM, Augusti Tocco G, Biagioni S. Detection of basal and potassium-evoked acetylcholine release from embryonic DRG explants. J Neurochem 2004; 88: 1533-19.
3. Grando SA, Pittelkow MR, Schellereunter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. J Invest Dermatol 2006; 126: 1948-65.
4. Kawashima K, Fujii T. Expression of non neuronal acetylcholine in lymphocytes and its contribution of immune function. Front Biosci 2004; 9: 2063-85.
5. Haberberger RV, Bodenbenner M, Kummer W. Expression of the cholinergic gene locus in pulmonary arterial endothelial cells. Histochem Cell Biol 2000; 113: 379-87.
6. Varoqui H, Erickson JD. Vesicular neurotransmitter transporters. Potential sites for the regulation of synaptic function. Mol Neurobiol 1997; 15: 165-91.
7. Nguyen ML, Cox GD, Parsons SM. Kinetic parameters for the vesicular acetylcholine transporters: two protons are exchanged for one acetylcholine. Biochemistry 1998; 37: 13400-10.
8. Cervini R, Houhou L, Pradat PF, et al. Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. J Biol Chem 1995; 270: 24654-7.
9. Weihe E, Schäfer MKH, Schütz B, et al. From the cholinergic gene locus to the cholinergic neurons. J Physiol 1998; 92: 385-8.
10. Rand JB, Duerr JS, Frisby DL. Neurogenetics of vesicular transporters in C. elegans. FASEB J 2000; 15: 2414-22.
11. Castell X, Diebler MF, Tomasi M, et al. More than one way to toy with ChAT and VAChT. J Physiol Paris 2002; 96: 61-72.
12. Madziar B, Shah S, Brock M, et al. Nerve growth factor regulates the expression of the cholinergic locus and the high-affinity choline transporter via the Akt/PKB signaling pathway. J Neurochem 2008; 107: 1284-93.
13. Brock M, Nickel AC, Madziar B, Blusztajn JK, Berse B. Differential regulation of the high affinity choline transporter and the cholinergic locus by cAMP signaling pathways. Brain Res 2007; 1145: 1-10.
14. Taylor P, Brown JH. Acetylcholine. In: Basic Neurochemistry. In: Siegel GJ, Agranoff BW, Albers RW, Molinoff PB, Eds. 5th ed., New York: Raven Press 1994; pp. 231-60.
15. Peralta EG, Ashkenazi A, Winslow JW, et al. Distint primary structures, ligand binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 1987; 6: 3923-9.
16. Caufield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-90.
17. Caufield MP. Muscarinic receptors: characterization, coupling and function. Pharmacol Ther 1993; 58: 319-79.
18. Nestler EJ, Duman RS. G proteins and cyclic nucleotides in the nervous system. In: Basic Neurochemistry; Siegel GJ, Agranoff BW, Albers RW, Molinoff PB, Eds.; Raven Press, 1994; pp. 231-60.
19. Loreti S, Vilaro MT, Visentin S, et al. Rat Schwann cells express M1-M4 muscarinic receptor subtypes. J Neurosci Res 2006; 84: 97-105.
20. De Angelis F, Bernardo A, Magnaghi V, Minghetti L, Tata AM. Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation, and differentiation. Devel Neurobiol 2012; 72: 713-28.
21. Biagioni S, Tata AM, De Jaco A, Augusti-Tocco G. Acetylcholine synthesis and neuron differentiation. Int J Dev Biol 2000; 44(6): 689-97.
22. Augusti-Tocco G, Biagioni S, Tata AM. Acetylcholine and regulation of gene expression in developing systems. J Mol Neurosci 2006; 30:45-8.
23. Karnovsky MJ, Roots, L. A direct coloring thiocholine method for cholinesterase. J Histochem Cytochem 1964; 12: 219-21.
24. Butcher LL. Acetylcholinesterase histochemistry. In: Handbook of Chemical Neuroanatomy. Björrklund A, Hökfelt T, Eds.; Elsevier, 1993; 1-49.
25. Kimura H, McGeer PL, Peng JH, McGeer EG. The central cholinergic system studied by choline acetyltransferase immunohistochemistry. J Comp Neurol 1981; 200: 151-201.
26. Levey AI, Wainer BH, Rye DB, Mufson EJ, Mesulam MM. Choline acetyltransferase-immunoreactive neurons intrinsic to rodent cortex and distinction from acetylcholinesterase positive neurons. Neuroscience 1984; 13: 341-53.
27. Cortes R, Arvidsson U, Schalling M, Ceccatelli S, Hökfelt T. In situ hybridization studies on mRNAs for cholecystokinin, calcitonin generelated peptide and choline acetyltransferase in lower brain stem, spinal cord and dorsal root ganglia of rat and guinea pig with special reference to motoneurons. J Chem Neuroanat 1990; 3: 47-85.
28. Butcher LL, Oh JD, Woolf NJ, Edwards RH, Roghani A. Organization of central cholinergic neurons revealed by combined in situ hybridization histochemistry and choline-O-acetyltransferase immunocytochemistry. Neurochem Int 1992; 21: 429-45.
29. Vilarò MT, Martinez-Mir MI, Sarasa M, et al. Molecular neuroanatomy of neurotransmitter receptors: the use of in situ hybridization histochemistry for the study of their anatomical and cellular localization. Curr Asp Neurosci 1991; 3: 1-36.
30. Vilarò MT, Wiederhold KH, Palacios JM, Mengod G. Muscarinic M2 receptor mRNA expression and receptor binding in cholinergic and non-cholinergic cells in the rat brain: a correlative study using in situ hybridization histochemistry and receptor autoradiography. Neuroscience 1992; 47: 367-93.
31. Woolf NJ, Butcher LL. Cholinergic neurons in the caudate-putamen complex proper are intrinsically organized: a combined Evans Blue and acetylcholinesterase analysis. Brain Res Bull 1985; 14: 63-83.
32. Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol 1997; 48: 649-84.
33. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983b; 214: 170-97.
34. Woolf, NJ. Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol 1991; 37: 475-824.
35. Newman EL, Gupta K, Climer JR, Monaghan CK, Hasselmo ME. Cholinergic modulation of cognitive processing: insights drawn from computational models. Front Behav Neurosci 2012; 6: 1-19.
36. Woolf NJ, Butcher LL. Cholinergic systems in the rat brain. III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal forebrain. Brain Res Bull 1986; 16: 603-37.
37. Woolf NJ, Butcher LL. Cholinergic systems in the rat brain. IV. Descending projections of the pontomesencephalic tegmentum. Brain Res Bull 1989; 23: 519-40.
38. Crowther RA. Structural aspects of pathology in Alzheimer's disease. Biochim Biophys Acta 1990; 1096: 1-9.
39. Abraham CR, Potter H. Alzheimer’s disease: recent advances in understanding the brain amyloidosis. Biotechnology 1989; 7: 147-53.
40. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer’s disease: implications for therapy. Am J Psychiatry 1994; 151: 1105-13.
41. Eikelenboom P, Rozemuller AJ, Hoozemans JJ, Veerhuis R, van Gool WA. Neuroinflammation and Alzheimer disease: clinical and therapeutic implication. Alzheimer Dis Assoc Disord 2000; 14(Suppl 1): S854-S861.
42. Praticò D, Trojanowski JQ. Inflammatory hypotheses: novel mechanisms of Alzheimer’s neurodegeneration and new therapeutic targets? Neurobiol Aging 2000; 21: 441-5.
43. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21: 383-21.
44. Blasko I, Veerhuis R, Stampfer-Kountchev M, et al. Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human. Neurobiol Dis 2000; 7(6 Pt B): 682-9.
45. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflamma-tion: implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch Med Res 2008; 39: 1-16.
46. Gitter BD, Cox LM, Rydel RE, May PC. Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. Proc Natl Acad Sci USA 1995; 92: 10738-41.
47. Iarlori C, Gambi D, Gambi F, et al. Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer’s disease. Exp Gerontol 2005; 40: 605-11.
48. Paganelli R, Di Iorio A, Patricelli L, et al. Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer’s disease patients. Exp Gerontol 2002; 37: 257-63.
49. Sala G, Galimberti G, Canevari C, et al. Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol Aging 2003; 24: 909-14.
50. Reale M, Kamal MA, Velluto L, et al. Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease. Curr Alzheimer Res 2012; 9: 447-57.
51. Quan N, Herkenham M. Connecting cytokines and brain: a review of current issues. Histol Histopathol 2002; 17: 273-88.
52. Pakaski M, Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer’s disease. Neurochem Int 2008; 53: 103-11.
53. Auld DS, Kar S, Quirion R. Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci 1998; 21: 43-9.
54. Mori F, Lai CC, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in brain cortex. Neuro Rep 1995; 6: 633-6.
55. Inestrosa N, Alvarez A, Perez CA, et al. Acetyl-cholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-91.
56. Hoshi M, Takashima A, Murayama M, et al. Nontoxic amyloid beta peptide1-42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. J Biol Chem 1997; 272: 2038-41.
57. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273-7.
58. Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005; 102: 17213-8
59. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47: 64-70.
60. Galdeano C, Viayna E, Sola I, et al. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. J Med Chem 2012; 55: 661-9.
61. Forlenza OV, Spink JM, Dayanandan R, et al. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm 2000; 107: 1201-12.
62. Fisher A, Brandeis R, Bar-Ner RH, et al. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci 2002; 19: 145-53.
63. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 2003; 28: 515-22.
64. Langstom JW. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591-6.
65. Lewy FH. Zur pathologischen Anatomie der Paralysis agitans. Dtsh Ztschr Nervenheilkunde 1913; 50: 50-5.
66. Bohnen NI, Albin RL. The Cholinergic System and Parkinson Disease. Behav Brain Res 2011; 221: 564-73.
67. Mesulam M, Mash D, Hersh L, Bothwell M, Geula C. Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. J Comp Neurol 1992; 323: 252-68.
68. Perez XA, Bordia T, McIntosh JM, Quik M. α6β2* and α4β2* Nicotinic Receptors Both Regulate Dopamine Signaling with Increased Nigrostriatal Damage: Relevance to Parkinson's Disease. Mol Pharmacol 2010; 78: 971-80.
69. Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007; 64: 990-7.
70. Quik M, Bordia TK. Nicotinic receptors as CNS targets for Parkinson’s disease. Biochem Pharmacol 2007; 74: 1224-34.
71. Brichta L, Greengard P, Flajolet M. Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems. Trends Neurosci 2013; 36: 543-54.
72. Threlfell S, Clements MA, Khodai T, et al. Striatal muscarinic receptors promote activity-dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J Neurosci 2010; 30: 3398-408.
73. Goldberg YP, Telenius H, Hayden MR. The molecular genetics of Huntington’s disease. Curr Opin Neurol 1994; 7: 325-32.
74. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-3.
75. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat issufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
76. Calabresi P, Centonze D, Pisani A, et al. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington’s disease. Ann Neurol 1998; 43: 586-97.
77. Aquilonius SM, Eckernas SA, Sundwall A. Regional distribution of choline acetyltransferase in the human brain: changes in Huntington’s chorea. J Neurol Neurosurg Psychiatry 1975; 38: 669-77.
78. Spokes EG. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 1980; 103(1): 179-210.
79. Smith R, Chung H, Rundquist S, et al. Cholinergic neuronal defect without cell loss in Huntington’s disease. Human Mol Gen 2006; 15: 3119-31.
80. Soldati C, Bithell A, Johnston C, et al. Dysregulation of RESTregulated coding and non-coding RNAs in a cellular model of Huntington’s disease. J Neurochem 2013; 124: 418-30.
81. Shimojo M. Huntingtin regulates RE1-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSF-interacting LIM domain protein (RILP) and dynactin p150 Glued. J Biol Chem 2008; 283: 34880-6.
82. Zuccato C, Tartari M, Crotti A, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Gen 2003; 35: 76-83.
83. Aquilonius SM, Eckernas SA. Choline therapy in Huntington chorea. Neurology 1997; 27: 887-89.
84. Tarsy D, Leopold N, Sax DS. Physostigmine in choreiform movement disorders. Neurology 1974; 24: 28-33.
85. Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington’s disease. Mov Disord 2000; 15: 173-6.
86. de Tommaso M, Specchio N, Sciruicchio V, Di Fruscolo O, Specchio LM. Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov Disord 2004; 19: 1516-8.
87. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-61.
88. Borovikova LV, Ivanova S, Nardi D, et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci 2000; 85: 141-7.
89. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nature Rev Immunol 2007; 7: 161-7.
90. Antonica A, Magni F, Mearini L, Paolocci N. Vagal control of lymphocyte release from rat thymus. J Auton Nerv Syst 1994; 48: 187-97.
91. Niijima A, Hori T, Katafuchi T, Ichijo T. The effect of interleukin-β on the efferent activity of the vagus nerve to the thymus. J Auton Nerv Syst 1995; 54: 137-44.
92. Hori T, Katafuchi T, Take S, Shimizu N, Niijima A. The autonomic nervous system as a communication channel between the brain and the immune system. Neuroimmunomodulation 1995; 2: 203-15.
93. de Jonge WJ, van der Zanden EP, The FO, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 2005; 6: 844-51.
94. Huston JM, Ochani M, Rosas-Ballina M, et al. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 2006; 203(7):1623-8.
95. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, Verdu EF, Collins SM. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology 2006; 131: 1122-30.
96. Sun P, Zhou K, Wang S, et al. Involvement of MAPK/NF-κB signaling in the activation of the cholinergic anti-inflammatory pathway in experimental colitis by chronic vagus nerve stimulation. PLoS One 2013; 8(8): e69424.
97. Tracey KJ. The inflammatory reflex. Nature 2002; 420: 853-9.
98. Blalock JE. Harnessing a neural-immune circuit to control inflammation and shock. J Exp Med 2002; 195: F25-8.
99. Rosas-Ballina M, Olafsson PS, Ochani M, et al. Acetylcholinesynthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011; 334: 98-101.
100. Grando, SA, Kawashima K, Wessler I. Introduction: The non-neuronal cholinergic system in humans. Life Sci 2003; 72: 2009-12.
101. Saeed RW, Varma S, Peng-Nemeroff T, et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 2005; 201: 1113-23.
102. Kawashima K, Fujii T. Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther 2000; 86: 29-48.
103. Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 2005; 4: 673-84.
104. Czura CJ, Friedman SG, Tracey KJ. Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway. J Endotoxin Res 2003; 9: 409-13.
105. Razani-Boroujerdi S, Behl M, Hahn FF, et al. Role of muscarinic receptors in the regulation of immune and inflammatory responses. J Neuroimmunol 2008; 194: 83-8.
106. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-8.
107. Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10: 1216-21.
108. Gallowitsch-Puerta M, Pavlov VA. Neuro-immune interactions via the cholinergic anti-inflammatory pathway. Life Sci 2007; 80: 2325-9.
109. de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 2007; 151(7): 915-29.
110. Sun Y, Li Q, Gui H, et al. MicroRNA-124 mediates the cholinergic anti-inflammatory action through inhibiting the production of proinflammatory cytokines. Cell Res 2013; 23: 1270-83.
111. Alam A, Shaikh S, Ahmad SS, et al. Molecular Interaction of Human Brain Acetylcholinesterase with a Natural Inhibitor Huperzine-B: An Enzoinformatics Approach. CNS Neurol Disord Drug Targets 2013; 13(3): 487-90.
112. Yu QS, Reale M, Kamal MA, et al. Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α -Synuclein synthesis, interleukin-1β release, and cholinergic action. Antiinflamm Antiallergy Agents Med Chem 2013; 12: 117-28.
113. Kamal MA, Qu X, Yu QS, et al. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J Neural Transm 2008; 115: 889-98.
114. Pollak Y, Gilboa A, Ben-Menachem O, et al. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1β production. Ann Neurol 2005; 57: 741-5.
115. Chensue SW, Terebuh PD, Remick DG, Scales WE, Kunkel SL. In vivo biological and immunohistochemical analysis of interleukin-1 α, β and tumor necrosis factor during experimental endotoxemia. Am J Pathol 1991; 138: 395-402.
116. Reale M, Iarlori C, Gambi F, et al. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1β and interleukin-6 release from lymphocytes of Alzheimer’s disease patients. Exp Gerontol 2005; 40: 165-71.
117. Soreq H, Wolf Y. NeurimmiRs: microRNAs in the neuroimmune interface. Trends Mol Med 2011; 17: 548-55.
118. Greig NH, Reale M, Tata AM. New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors. Rec Pat CNS Drug Discov 2013; 8: 123-41.
119. Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci 2003; 74: 675-96.